BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Doxorubicin
,
rs3825942
,
PBX1
,
Fatty acid metabolic process
,
Inflammatory disorder
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
Recurrent pterygium
(phenotype)
Summary
General Info
Genetic Markers
Most Correlated Genes
Most Correlated SNPs
No genes found
No SNPs found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
No studies found
Explore Curated Studies Results
Literature
Most Relevant Literature
Topical application of bevacizumab as an adjunct to recurrent pterygium surgery.
Transplantation of the Bowman's layer in combined treatment of recurrent pterygium].
Pre- and intraoperative mitomycin C for recurrent pterygium associated with symblepharon.
Comparative evaluation of lymphatic vessels in primary versus recurrent pterygium.
Relationship between angiogenesis and lymphangiogenesis in recurrent pterygium.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Bevacizumab Injection for Recurrent Pterygium
Strategies for Management of Recurrent Pterygium
Subconjunctival Bevacizumab and Recurrent Pterygium
Topical Bevacizumab for Preventing Recurrent Pterygium
Conjunctival Autograft or Limbal Conjunctival Autograft for Recurrent Pterygium Using Mitomycin C
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ